About Neuropace, Inc. Common Stock (NPCE)

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures.

NPCE trading today

NPCE has traded between $5.46 and $7.71 in the current session, a range of $2.25. The latest price of $7.16 sits in the middle of that range (76% of the way from low to high). It opened at $6.25, a gap down of 48.00% from the prior close of $12.02. The volume-weighted average price is $6.43, and the stock is trading above it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.

Where NPCE holders stand

StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-16 and 2026-11-14 were bought. Its estimate of the average cost basis is $9.02; at $7.16 the stock trades 20.6% below that level. About 54.9% of those shares are estimated to be held at a profit at the current price. A figure in the middle means holders are split between gains and losses. The densest nearby clusters of cost basis sit around $5.54 (support) and $7.56 (resistance). Roughly 70% of the estimated cost basis lies between $5.97 and $13.37, and 90% between $5.63 and $14.38.

This is a model estimate built from price and volume history, not a record of actual positions.

How to read this page

Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.